Cost Plus Drugs Moves Into Experimental Rare Disease Therapies

Cost Plus Drugs is beginning to move beyond generic medicines, taking on the more complex business of experimental therapies for rare diseases. That shift could broaden the role of Mark Cuban’s online pharmacy, which aims to reduce drug costs by bypassing middlemen. The distinction matters: generic drugs are copies of medicines whose patents have expired, while experimental therapies are still being developed and may have uncertain clinical and commercial paths. A company entering that area would face questions that a low price on an established generic doesn’t answer, including how a treatment is developed, who can access it, and how its cost is handled.

The move follows an intriguing email Cuban sent a STAT colleague last spring, which set a story in motion. The details of the company’s rare disease plans weren’t included in the available report, so the scope and structure of the effort remain unclear. That leaves open whether Cost Plus Drugs intends to support drug development, help bring therapies to patients, or pursue another role. The distinction is consequential: “experimental therapies” can refer to work at very different stages, and the demands on a pharmacy would depend on what the company actually plans to do.

From generic pricing to experimental therapies

Cost Plus Drugs’ stated approach is built around reducing drug costs by bypassing middlemen. That model has a relatively clear point of comparison when a medicine is already available as a generic: the drug exists, and the business question centers on how it’s priced and distributed. Rare disease therapies can be a different proposition. Their development may involve specialized research, small patient populations, and difficult decisions about how to test whether a treatment works.

That doesn’t mean a pharmacy can’t have a role. It does mean the label “online pharmacy” may not explain the full business if the company moves into experimental medicine. In this category, the work can extend beyond dispensing a finished product. The company’s plans would need to clarify where it fits in the process and which parts of the drug’s path it intends to influence.

For patients and families facing rare diseases, the promise of a new therapy can carry particular weight when existing options are limited. But the prospect of treatment and the evidence that a treatment works are separate matters. Experimental drugs must still be evaluated, and their development can be complicated by the small number of people affected by any one condition. A lower-cost approach to medicines could be relevant, but it can’t by itself resolve those scientific and practical challenges.

What the company hasn’t disclosed

The available report gives little detail about Cost Plus Drugs’ rare disease plans. It doesn’t identify a therapy, describe a development program, or explain how the company would participate. Those omissions make it premature to treat the move as a defined expansion into drug development. The clearest conclusion is narrower: the company is signaling interest in an area beyond the generic medicines that have largely shaped its identity.

Here’s the thing: the company’s reputation for challenging drug prices may lead readers to assume that a similar approach can be applied directly to experimental therapies. It may not. The cost of a generic and the cost of developing a new treatment come from different parts of the medicine business. A plan to reduce the price of an available drug doesn’t, on its own, show how a company would fund research or manage the uncertainty of clinical development.

That said, the move could still test how much of Cost Plus Drugs’ model travels beyond established medicines. If you’re working in this space, the key question is what the company will actually do: develop therapies, partner with others, or focus on access after a drug is available. And this is the part most people overlook: the company’s role could matter as much as the therapies themselves. A change in business focus, without further detail, is a signal rather than proof of a new operating model.

Other biotech news

Roivant and subsidiary Priovant reported positive results from two Phase 3 studies of Lisraya for non-infectious uveitis, an inflammatory eye disease that can cause vision loss. Phase 3 studies are generally designed to assess a treatment in larger groups of patients and provide evidence relevant to an approval decision. Positive results are encouraging, but the report doesn’t include the study data needed to judge the size or reliability of the benefit. Encouraging, but incomplete.

The drug was recently approved for dermatomyositis. Roivant said it plans to seek expanded FDA approval for uveitis in the first half of 2027. An application would put the company’s reported trial results into a separate review process for this condition; approval for dermatomyositis doesn’t establish that the drug will be approved for uveitis. The planned filing gives the studies a concrete next step, while leaving the outcome unresolved.

Why the next details matter

Together, the two items point to different stages of the biotech business. Roivant and Priovant are reporting late-stage trial results for a drug that already has an approval for another condition. Cost Plus Drugs, by contrast, is described as beginning to explore rare disease therapies, with the details still missing. One story is about evidence generated in clinical studies; the other is about a possible change in a company’s focus.

This is more significant than it looks if Cost Plus Drugs can show that its approach has a useful role in rare disease treatment. But the available information doesn’t establish how it intends to do that, or whether its pricing strategy can address the challenges of experimental therapies. The next disclosures will need to explain the company’s role and the stage of the work. Until then, the shift is notable for the direction it suggests, not for a demonstrated result.